Efficacy of Sublingual Cyclobenzaprine for Fibromyalgia Pain and Sleep Improvement
Overview
This phase 3 randomized controlled trial demonstrated that bedtime TNX-102 SL (sublingual cyclobenzaprine) 5.6 mg significantly reduced pain intensity and improved sleep quality, fatigue, and overall fibromyalgia symptoms compared to placebo. The treatment was generally well tolerated, with mostly mild and transient oral administration-site adverse events.
Background
Fibromyalgia is a chronic nociplastic pain syndrome characterized by widespread pain, nonrestorative sleep, and fatigue, affecting approximately 6.4% of adults in the United States, predominantly women. Poor sleep quality contributes to symptom severity and flare-ups in fibromyalgia. Current pharmacologic treatments have limited efficacy on sleep and fatigue and are often poorly tolerated, highlighting the need for better therapies. Cyclobenzaprine, a tricyclic compound, has shown limited benefit in oral form, but sublingual cyclobenzaprine (TNX-102 SL) offers improved pharmacokinetics and potential symptom relief.
TNX-102 SL 5.6 mg significantly reduced weekly average daily pain intensity at 14 weeks compared to placebo (mean change -1.8 vs -1.2; P < .001).
All six secondary endpoints, including patient global impression of change, fibromyalgia symptoms and function, sleep disturbance, fatigue, and sleep quality, showed significant improvement with TNX-102 SL versus placebo (P ≤ .001).
The treatment was well tolerated with a similar trial completion rate between TNX-102 SL (81.0%) and placebo (79.6%).
The most common systemic adverse events were mild and included COVID-19, headache, and somnolence, occurring slightly more often with TNX-102 SL.
Local administration-site adverse events such as oral hypoesthesia, abnormal taste, and oral paresthesia were more frequent with TNX-102 SL but were transient and self-limited.
These results confirm prior phase 3 findings supporting the efficacy of sublingual cyclobenzaprine in fibromyalgia symptom management.
Clinical Implications
Bedtime administration of TNX-102 SL 5.6 mg offers a promising treatment option for fibromyalgia patients by targeting both pain and nonrestorative sleep, addressing core symptoms simultaneously. Its favorable safety profile and tolerability may improve patient adherence compared to existing therapies. Clinicians should consider this therapy for patients inadequately managed with current fibromyalgia treatments, especially those with prominent sleep disturbances.
Conclusion
TNX-102 SL 5.6 mg administered at bedtime significantly improves pain, sleep quality, fatigue, and overall fibromyalgia symptoms with good tolerability. This therapy represents an effective and well-tolerated option for managing fibromyalgia's complex symptomatology.
References
Arnold et al. 2023 -- Efficacy of Sublingual Cyclobenzaprine for Pain Management in Fibromyalgia: Results from a Phase 3 Randomized Controlled Trial
